Clinical ResearchHypertrophic CardiomyopathyPrognostic Significance of Myocardial Fibrosis in Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy
Under an Elsevier user license
open archive
Key Words
cardiovascular magnetic resonance
hypertrophic cardiomyopathy
late gadolinium enhancement
myocardial fibrosis
Abbreviations and Acronyms
BSA
body surface area
CI
confidence interval
CMR
cardiovascular magnetic resonance
FWHM
full width half maximum
HCM
hypertrophic cardiomyopathy
HF
heart failure
HR
hazard ratio
ICD
implantable cardioverter-defibrillator
LAVi
left atrial volume index
LGE
late gadolinium enhancement
LVOTO
left ventricular outflow tract obstruction
NSVT
nonsustained ventricular tachycardia
NYHA
New York Heart Association
SCD
sudden cardiac death
Cited by (0)
Research support was received from the National Institutes of Health Cardiovascular Biomedical Research Unit, British Heart Foundation, and (a registered charity). Dr. O'Hanlon was supported by the Department of Health, Ireland. Dr. Cowie has consultancy agreements with Pfizer, Takeda, and Servier. Dr. Pennell has received consultant/research support from Siemens, and is a director for Cardiovascular Imaging Solutions. All other authors have reported that they have no relationships to disclose.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.